Relmada Therapeutics

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

FDA written feedback supports: a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026. 12 January 2026 -- Florida, US -- Relmada Therapeutics, Inc, a clinical-stage biotechnology company advancing innovative therapies...
2222 Ponce de Leon Blvd. Floor 3 Coral Gables, FL 33134

+1 (786) 629-1376